Dynamic Carbon Dioxide (CO2) Administration for Sleep Apnoea

Status Not yet recruiting

Clinical Trial Summary

Normally breathing is controlled by a reflex that responds to the levels of carbon dioxide (CO2) in the blood. In heart failure, where the heart muscle is damaged and therefore does not pump as well, this reflex is exaggerated. The result is a vicious circle: blood CO2 levels fluctuate wildly and as a result breathing also fluctuates with patients hyperventilating at times and briefly stopping breathing at others. During sleep this is called central sleep apnoea (CSA).

Patients with CSA wake up throughout the night and whilst some patients are oblivious to this, others are consciously breathless and many patients are tired during the day and feel unable to perform their daily activities.

As part of the body's stress response to the erratic pattern of breathing, both blood pressure and heart rate may rise to a level that is harmful in a failing heart, exacerbating the underlying heart failure. Indeed patients who demonstrate this CSA die sooner than those who have heart failure and stable breathing.

There are no proven specific therapies for CSA that stabilise breathing, improve sleep quality, and prolong life. We have designed a system which delivers very small doses of CO2, when the blood level of CO2 is predicted to be low. During short daytime recordings, using this system, we have demonstrated that it is possible to stabilise the body's CO2 levels.

We aim to test what happens when CO2 is given overnight whilst the patient is sleeping to see whether we can stabilise their breathing over longer durations and whether sleep quality could be improved so that patients are less tired during the day. In addition, we would like to measure whether the stress response is lessened if the breathing is successfully stabilised.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01041924
Study type	Interventional
Source	Imperial College London
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	February 2010
Completion date	October 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01199042` - Bipap autoSV Advanced in Central Apnea Patients	N/A
Recruiting	`NCT03031626` - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome	Phase 4
Withdrawn	`NCT03238937` - Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea	N/A
Terminated	`NCT02820441` - Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance	Phase 4
Completed	`NCT00811668` - Comparison of CPAP With SOMNOventCR in Patients With Underlying Heart Disease, Combined OSA and CSR	N/A
Recruiting	`NCT03432910` - Application of Forced Breath Technique While CPAP Therapy for Apnea Classification	N/A
Withdrawn	`NCT04630639` - Sparkle Respiratory Effort Validation	N/A
Completed	`NCT01816776` - Respicardia, Inc. Pivotal Trial of the remedē System	N/A
Completed	`NCT04926077` - DreamKit Respiratory Effort Signal Validation	N/A
Completed	`NCT01626989` - Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders	N/A
Recruiting	`NCT04399200` - Apnea, Stroke and Incident Cardiovascular Events
Completed	`NCT04671342` - DreamKit Diagnostic Validation	N/A
Completed	`NCT00823134` - Evaluation of ApneaLink Plus Scoring Capabilities	N/A
Completed	`NCT05037032` - Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude	Phase 4
Completed	`NCT03552133` - Variable Dead Space Rebreathing Device to Treat Sleep Apnea	N/A
Completed	`NCT00720213` - Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device	N/A
Active, not recruiting	`NCT02554487` - Early Sleep Apnea Treatment in Stroke	N/A